Diabetic Retinopathy and Vision Loss: A Public Health Concern

Jossias Genao Cruz; Deepkumar Patel; Karen Allison*

Jossias Genao Cruz, Deepkumar Patel and Karen Allison*

Volume5-Issue7
Dates: Received: 2024-06-20 | Accepted: 2024-07-04 | Published: 2024-07-05
Pages: 691-698

Abstract

Diabetic Retinopathy (DR), a known complication of diabetes, is one of the top three leading causes of blindness in the U.S. Minorities are disproportionately affected and, most often, diagnosed at advanced stages. This review consolidates current epidemiological data, pathophysiological insights, clinical classifications, and treatment approaches for DR. Despite advancements in therapies like anti-VEGF drugs and laser treatments, significant disparities persist, particularly affecting racial minorities and those with lower socioeconomic status. Early detection via regular eye exams and improved healthcare access are crucial in mitigating DR's increasing global impact. Public health strategies must address these disparities and ensure inclusivity in clinical research to improve DR management and outcomes. Continued awareness of primary and secondary forms of prevention is crucial in all populations with DR, especially minorities, because progression to severe stages can be recognized, treated, and ameliorated. Although anti-vascular endothelial growth factors have advanced, further research is needed to aid understanding of DR in populations disproportionately affected by severe diseases.

FullText HTML FullText PDF DOI: 10.37871/jbres1944

Certificate of Publication

Copyright

How to cite this article

Cruz JG, Patel D, Allison K. Diabetic Retinopathy and Vision Loss: A Public Health Concern. J Biomed Res Environ Sci. 2024 Jul 05; 5(7): 691-698. doi: 10.37871/jbres1944, Article ID: JBRES1944, Available at: https://www.jelsciences.com/articles/ jbres1944.pdf

Subject area(s)

Ophthalmology

Public Health

References

National and State Diabetes Trends. CDC.
Diabetes Quick Facts. Basics. Diabetes. CDC.
Cha AE, Villarroel MA, Vahratian A. Eye Disorders and Vision Loss Among U.S. Adults Aged 45 and Over With Diagnosed Diabetes, 2016-2017. NCHS Data Brief. 2019 Jul;(344):1-8. PMID: 31442198.
Fairless E, Nwanyanwu K. Barriers to and Facilitators of Diabetic Retinopathy Screening Utilization in a High-Risk Population. J Racial Ethn Health Disparities. 2019 Dec;6(6):1244-1249. doi: 10.1007/s40615-019-00627-3. Epub 2019 Aug 28. PMID: 31463812; PMCID: PMC6880869.
Lee R, Wong TY, Sabanayagam C. Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss. Eye Vis (Lond). 2015 Sep 30;2:17. doi: 10.1186/s40662-015-0026-2. PMID: 26605370; PMCID: PMC4657234.
Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, Colagiuri S, Guariguata L, Motala AA, Ogurtsova K, Shaw JE, Bright D, Williams R; IDF Diabetes Atlas Committee. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract. 2019 Nov;157:107843. doi: 10.1016/j.diabres.2019.107843. Epub 2019 Sep 10. PMID: 31518657.
Graham DO, Wang F, Gregory GA, Maniam J. Type 1 diabetes estimates in children and adults. International Diabetes Federation.
Teo ZL, Tham YC, Yu M, Chee ML, Rim TH, Cheung N, Bikbov MM, Wang YX, Tang Y, Lu Y, Wong IY, Ting DSW, Tan GSW, Jonas JB, Sabanayagam C, Wong TY, Cheng CY. Global Prevalence of Diabetic Retinopathy and Projection of Burden through 2045: Systematic Review and Meta-analysis. Ophthalmology. 2021 Nov;128(11):1580-1591. doi: 10.1016/j.ophtha.2021.04.027. Epub 2021 May 1. PMID: 33940045.
Lee R, Wong TY, Sabanayagam C. Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss. Eye Vis (Lond). 2015 Sep 30;2:17. doi: 10.1186/s40662-015-0026-2. PMID: 26605370; PMCID: PMC4657234.
Yau JW, Rogers SL, Kawasaki R, Lamoureux EL, Kowalski JW, Bek T, Chen SJ, Dekker JM, Fletcher A, Grauslund J, Haffner S, Hamman RF, Ikram MK, Kayama T, Klein BE, Klein R, Krishnaiah S, Mayurasakorn K, O'Hare JP, Orchard TJ, Porta M, Rema M, Roy MS, Sharma T, Shaw J, Taylor H, Tielsch JM, Varma R, Wang JJ, Wang N, West S, Xu L, Yasuda M, Zhang X, Mitchell P, Wong TY; Meta-Analysis for Eye Disease (META-EYE) Study Group. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012 Mar;35(3):556-64. doi: 10.2337/dc11-1909. Epub 2012 Feb 1. PMID: 22301125; PMCID: PMC3322721.
Health and economic benefits of diabetes interventions. Power of Prevention.
Patel D, Ananthakrishnan A, Lin T, Channa R, Liu TYA, Wolf RM. Social Determinants of Health and Impact on Screening, Prevalence, and Management of Diabetic Retinopathy in Adults: A Narrative Review. J Clin Med. 2022 Nov 30;11(23):7120. doi: 10.3390/jcm11237120. PMID: 36498694; PMCID: PMC9739502.
Barsegian A, Kotlyar B, Lee J, Salifu MO, McFarlane SI. Diabetic Retinopathy: Focus on Minority Populations. Int J Clin Endocrinol Metab. 2017;3(1):034-45. doi: 10.17352/ijcem.000027. Epub 2017 Nov 11. PMID: 29756128; PMCID: PMC5945200.
Zhang X, Cotch MF, Ryskulova A, Primo SA, Nair P, Chou CF, Geiss LS, Barker LE, Elliott AF, Crews JE, Saaddine JB. Vision health disparities in the United States by race/ethnicity, education, and economic status: findings from two nationally representative surveys. Am J Ophthalmol. 2012 Dec;154(6 Suppl):S53-62.e1. doi: 10.1016/j.ajo.2011.08.045. PMID: 23158224; PMCID: PMC4169111.
Antonetti DA, Silva PS, Stitt AW. Current understanding of the molecular and cellular pathology of diabetic retinopathy. Nat Rev Endocrinol. 2021 Apr;17(4):195-206. doi: 10.1038/s41574-020-00451-4. Epub 2021 Jan 19. PMID: 33469209; PMCID: PMC9053333.
Klein R, Knudtson MD, Lee KE, Gangnon R, Klein BE. The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XXII the twenty-five-year progression of retinopathy in persons with type 1 diabetes. Ophthalmology. 2008 Nov;115(11):1859-68. doi: 10.1016/j.ophtha.2008.08.023. PMID: 19068374; PMCID: PMC2761813.
Forrester JV, Kuffova L, Delibegovic M. The Role of Inflammation in Diabetic Retinopathy. Front Immunol. 2020 Nov 6;11:583687. doi: 10.3389/fimmu.2020.583687. PMID: 33240272; PMCID: PMC7677305.
Rodriguez-Fontal M, Kerrison JB, Alfaro DV, Jablon EP. Metabolic control and diabetic retinopathy. Curr Diabetes Rev. 2009 Feb;5(1):3-7. doi: 10.2174/157339909787314176. PMID: 19199891.
Frank RN. Diabetic retinopathy and systemic factors. Middle East Afr J Ophthalmol. 2015 Apr-Jun;22(2):151-6. doi: 10.4103/0974-9233.154388. PMID: 25949071; PMCID: PMC4411610.
Diabetes Control and Complications Trial Research Group; Nathan DM, Genuth S, Lachin J, Cleary P, Crofford O, Davis M, Rand L, Siebert C. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993 Sep 30;329(14):977-86. doi: 10.1056/NEJM199309303291401. PMID: 8366922.
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998 Sep 12;352(9131):837-53. Erratum in: Lancet 1999 Aug 14;354(9178):602. PMID: 9742976.
Penman A, Hancock H, Papavasileiou E, James M, Idowu O, Riche DM, Fernandez M, Brauner S, Smith SO, Hoadley S, Richardson C, Vazquez V, Chi C, Andreoli C, Husain D, Chen CJ, Sobrin L. Risk Factors for Proliferative Diabetic Retinopathy in African Americans with Type 2 Diabetes. Ophthalmic Epidemiol. 2016;23(2):88-93. doi: 10.3109/09286586.2015.1119287. Epub 2016 Mar 7. PMID: 26950197; PMCID: PMC4851860.
Silva PS, Cavallerano JD, Sun JK, Aiello LM, Aiello LP. Effect of systemic medications on onset and progression of diabetic retinopathy. Nat Rev Endocrinol. 2010 Sep;6(9):494-508. doi: 10.1038/nrendo.2010.122. Epub 2010 Jul 27. PMID: 20664533.
Saini DC, Kochar A, Poonia R. Clinical correlation of diabetic retinopathy with nephropathy and neuropathy. Indian J Ophthalmol. 2021 Nov;69(11):3364-3368. doi: 10.4103/ijo.IJO_1237_21. PMID: 34708806; PMCID: PMC8725070.
Dahl-Jørgensen K, Brinchmann-Hansen O, Hanssen KF, Ganes T, Kierulf P, Smeland E, Sandvik L, Aagenaes O. Effect of near normoglycaemia for two years on progression of early diabetic retinopathy, nephropathy, and neuropathy: the Oslo study. Br Med J (Clin Res Ed). 1986 Nov 8;293(6556):1195-9. doi: 10.1136/bmj.293.6556.1195. PMID: 3096429; PMCID: PMC1341978.
Mohamed Q, Gillies MC, Wong TY. Management of diabetic retinopathy: a systematic review. JAMA. 2007 Aug 22;298(8):902-16. doi: 10.1001/jama.298.8.902. PMID: 17712074.
Flaxel CJ, Adelman RA, Bailey ST, Fawzi A, Lim JI, Vemulakonda GA, Ying GS. Diabetic Retinopathy Preferred Practice Pattern®. Ophthalmology. 2020 Jan;127(1):P66-P145. doi: 10.1016/j.ophtha.2019.09.025. Epub 2019 Sep 25. Erratum in: Ophthalmology. 2020 Sep;127(9):1279. doi: 10.1016/j.ophtha.2020.06.047. PMID: 31757498.
Diabetic Retinopathy Clinical Research Network; Wells JA, Glassman AR, Ayala AR, Jampol LM, Aiello LP, Antoszyk AN, Arnold-Bush B, Baker CW, Bressler NM, Browning DJ, Elman MJ, Ferris FL, Friedman SM, Melia M, Pieramici DJ, Sun JK, Beck RW. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med. 2015 Mar 26;372(13):1193-203. doi: 10.1056/NEJMoa1414264. Epub 2015 Feb 18. PMID: 25692915; PMCID: PMC4422053.
Grisanti S, Ziemssen F. Bevacizumab: off-label use in ophthalmology. Indian J Ophthalmol. 2007 Nov-Dec;55(6):417-20. doi: 10.4103/0301-4738.36474. PMID: 17951896; PMCID: PMC2635984.
Sanjiv N, Osathanugrah P, Harrell M, Siegel NH, Ness S, Chen X, Cabral H, Subramanian ML. Race and ethnic representation among clinical trials for diabetic retinopathy and diabetic macular edema within the United States: A review. J Natl Med Assoc. 2022 Apr;114(2):123-140. doi: 10.1016/j.jnma.2021.12.016. Epub 2022 Jan 22. PMID: 35078668.
Houle J, Lauzier-Jobin F, Beaulieu MD, Meunier S, Coulombe S, Côté J, Lespérance F, Chiasson JL, Bherer L, Lambert J. Socioeconomic status and glycemic control in adult patients with type 2 diabetes: a mediation analysis. BMJ Open Diabetes Res Care. 2016 May 11;4(1):e000184. doi: 10.1136/bmjdrc-2015-000184. PMID: 27239316; PMCID: PMC4873951.
Nathan DM; DCCT/EDIC Research Group. The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: overview. Diabetes Care. 2014;37(1):9-16. doi: 10.2337/dc13-2112. PMID: 24356592; PMCID: PMC3867999.
Calderon GD, Juarez OH, Hernandez GE, Punzo SM, De la Cruz ZD. Oxidative stress and diabetic retinopathy: development and treatment. Eye (Lond). 2017 Aug;31(8):1122-1130. doi: 10.1038/eye.2017.64. Epub 2017 Apr 28. PMID: 28452994; PMCID: PMC5558229.
Wykoff CC. Management of Diabetes-Related Retinopathy. 2019 May. In: Prevention and Management of Diabetes-Related Eye Disease. Arlington (VA): American Diabetes Association; 2019 May. PMID: 34251786.
Spanakis EK, Golden SH. Race/ethnic difference in diabetes and diabetic complications. Curr Diab Rep. 2013 Dec;13(6):814-23. doi: 10.1007/s11892-013-0421-9. PMID: 24037313; PMCID: PMC3830901.
Czapp P, Kovach. Poverty and health- The family medicine perspective (position paper). American Academy of Family Physicians. 2015.
Golden SH, Brown A, Cauley JA, Chin MH, Gary-Webb TL, Kim C, Sosa JA, Sumner AE, Anton B. Health disparities in endocrine disorders: biological, clinical, and nonclinical factors--an Endocrine Society scientific statement. J Clin Endocrinol Metab. 2012 Sep;97(9):E1579-639. doi: 10.1210/jc.2012-2043. Epub 2012 Jun 22. PMID: 22730516; PMCID: PMC3431576.
Li J, Harrison WJ, Cho SK. Disparity in diabetic eye complications among racial/ethnic minorities: An analysis of the 2009-2018 United States Medical Expenditure Panel Survey. Diabetes Epidemiology and Management. 2022;6:100070. doi: 10.1016/j.deman.2022.100070.
Scheen AJ. Dual GIP/GLP-1 receptor agonists: New advances for treating type-2 diabetes. Ann Endocrinol (Paris). 2023 Apr;84(2):316-321. doi: 10.1016/j.ando.2022.12.423. Epub 2023 Jan 10. PMID: 36639119.